Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15294883 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Withdrawn Lucentis for New Onset Neovascular Glaucoma
Conditions: Glaucoma;   New Onset Glaucoma;   Neovascular Glaucoma;   New Onset Neovascular Glaucoma
Intervention: Drug: Ranibizumab (Lucentis)

Indicates status has not been verified in more than two years